Fu Shujuan, Wang Zhiying, Li Cunya, Li Yun, Zhang Ke, Zhong Zhixian, Zhong Yi
Oncology Department, Shanghai TCM-Intergrated Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Oncol. 2023 May 2;13:1094770. doi: 10.3389/fonc.2023.1094770. eCollection 2023.
Primary nuclear protein in testis (NUT) carcinoma is a rare malignant tumor originating from the salivary glands that usually occurs in midline structures, such as the head and neck, and has been identified in young patients. Progression of NUT carcinoma is rapid, and there is a high degree of malignant invasion. The median survival time of NUT carcinoma patients is 6 to 9 months, and 80% of the patients die within 1 year after diagnosis.
This case report summarizes the treatment of a 36-year-old male patient with NUT carcinoma of the right parotid gland. The overall survival of the patient was 2 years. We also discuss the applications and outcomes of immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of NUT carcinoma.
We suggest that targeted therapy combined with immunotherapy which has long-term clinical benefits and targeted therapy which has high clinical response rate(immunotherapy + dual-targeting three-drug regimens) is an ideal choice for the treatment of patients with rare and/or refractory tumors and will not compromise patient safety.
identifier ChiCTR1900026300.
睾丸原发性核蛋白（NUT）癌是一种罕见的恶性肿瘤，起源于唾液腺，通常发生在中线结构，如头颈部，多见于年轻患者。NUT癌进展迅速，具有高度恶性侵袭性。NUT癌患者的中位生存时间为6至9个月，80%的患者在诊断后1年内死亡。
本病例报告总结了一名36岁右腮腺NUT癌男性患者的治疗情况。该患者的总生存期为2年。我们还讨论了免疫检查点抑制剂和靶向治疗联合方案在NUT癌治疗中的应用及疗效。
我们认为，具有长期临床获益的靶向治疗联合免疫治疗以及具有高临床缓解率的靶向治疗（免疫治疗+双靶点三联方案）是治疗罕见和/或难治性肿瘤患者的理想选择，且不会影响患者安全。
标识符ChiCTR1900026300
